BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 24060699)

  • 1. Gut hormones as therapeutic agents in treatment of diabetes and obesity.
    Tan T; Bloom S
    Curr Opin Pharmacol; 2013 Dec; 13(6):996-1001. PubMed ID: 24060699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gut hormone analogues and skeletal health in diabetes and obesity: Evidence from preclinical models.
    Mabilleau G; Bouvard B
    Peptides; 2024 Jul; 177():171228. PubMed ID: 38657908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Future therapies for obesity.
    Melson E; Miras AD; Papamargaritis D
    Clin Med (Lond); 2023 Jul; 23(4):337-346. PubMed ID: 37524416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The intestine as an endocrine organ and the role of gut hormones in metabolic regulation.
    Bany Bakar R; Reimann F; Gribble FM
    Nat Rev Gastroenterol Hepatol; 2023 Dec; 20(12):784-796. PubMed ID: 37626258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of cereal soluble fiber in the beneficial modulation of glycometabolic gastrointestinal hormones.
    Kabisch S; Weickert MO; Pfeiffer AFH
    Crit Rev Food Sci Nutr; 2024; 64(13):4331-4347. PubMed ID: 36382636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No Guts, No Loss: Toward the Ideal Treatment for Obesity in the Twenty-First Century.
    Hope DCD; Tan TMM; Bloom SR
    Front Endocrinol (Lausanne); 2018; 9():442. PubMed ID: 30158899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A newly identified gut hormone suppresses cholesterol production in the liver.
    Fernández-Ruiz I
    Nat Rev Cardiol; 2024 Jun; 21(6):358. PubMed ID: 38548956
    [No Abstract]   [Full Text] [Related]  

  • 8. Commentary on "The road to reliable peptide assays is paved with good guidelines".
    Kowalka AM; Alexiadou K; Cuenco J; Clarke RE; Camuzeaux S; Minnion J; Williams EL; Bech P; Purkayastha S; Ahmed AR; Takats Z; Khoo B; Whitwell HJ; Romero MG; Bloom SR; Lewis MR; Tan TM
    Clin Endocrinol (Oxf); 2023 Jun; 98(6):763-765. PubMed ID: 36915993
    [No Abstract]   [Full Text] [Related]  

  • 9. The future role of gut hormones in the treatment of obesity.
    Troke RC; Tan TM; Bloom SR
    Ther Adv Chronic Dis; 2014 Jan; 5(1):4-14. PubMed ID: 24381724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enteroendocrine secretion of gut hormones in diabetes, obesity and after bariatric surgery.
    Holst JJ
    Curr Opin Pharmacol; 2013 Dec; 13(6):983-8. PubMed ID: 24161809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of gastrointestinal hormones in the pathogenesis of obesity and type 2 diabetes.
    Adamska E; Ostrowska L; Górska M; Krętowski A
    Prz Gastroenterol; 2014; 9(2):69-76. PubMed ID: 25061485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between gut hormones and glucose homeostasis after bariatric surgery.
    Sala PC; Torrinhas RS; Giannella-Neto D; Waitzberg DL
    Diabetol Metab Syndr; 2014; 6(1):87. PubMed ID: 25152774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormonal signaling in the gut.
    Côté CD; Zadeh-Tahmasebi M; Rasmussen BA; Duca FA; Lam TKT
    J Biol Chem; 2014 Apr; 289(17):11642-11649. PubMed ID: 24577102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treating obesity: is it all in the gut?
    Davenport RJ; Wright S
    Drug Discov Today; 2014 Jul; 19(7):845-58. PubMed ID: 24291217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diabetes and weight in comparative studies of bariatric surgery vs conventional medical therapy: a systematic review and meta-analysis.
    Ribaric G; Buchwald JN; McGlennon TW
    Obes Surg; 2014 Mar; 24(3):437-55. PubMed ID: 24374842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enteroendocrine hormone mimetics for the treatment of obesity and diabetes.
    Irwin N; Flatt PR
    Curr Opin Pharmacol; 2013 Dec; 13(6):989-95. PubMed ID: 24064397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel approaches to anti-obesity drug discovery with gut hormones over the past 10 years.
    Rose F; Bloom S; Tan T
    Expert Opin Drug Discov; 2019 Nov; 14(11):1151-1159. PubMed ID: 31355685
    [No Abstract]   [Full Text] [Related]  

  • 18. Self-assembled GLP-1/glucagon peptide nanofibrils prolong inhibition of food intake.
    Ouberai MM; Gomes Dos Santos AL; Kinna S; Hornigold DC; Baker D; Naylor J; Liang L; Corkill DJ; Welland ME
    Front Endocrinol (Lausanne); 2023; 14():1217021. PubMed ID: 37554763
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.